Immunotec Inc.
TSX CROISSANCE : IMM
TSX VENTURE : IMM

Immunotec Inc.

September 25, 2008 23:59 ET

Immunotec announces third quarter financial results

VAUDREUIL-DORION, QC, Sept. 25 - Immunotec Inc. (TSX-V: IMM)
(the "Company" or "Immunotec"), is engaged primarily in the development,
manufacturing and marketing of health and wellness products which are
classified as nutraceuticals, dietary supplements, or natural health products.
These products are distributed and sold in Canada and the United States
through a network marketing system and in other countries under
distributorship agreements.

HIGHLIGHTS

The Company, for the third quarter ended July 31, 2008, realized net
sales of $8,942,007 compared to $8,526,260 in 2007, an increase of $415,747 or
4.9%. By individual markets and in their respective local currencies, net
sales in Canada posted an increase of 5%, the U.S. market posted an increase
of 11.8% and International markets realized a 63.9% increase.

For the third quarter, net sales by final destination were as follows;
49.5% in Canada and 40.0% in the United States, with the remainder 10.5%,
through export to other International markets.



SELECTED CONSOLIDATED FINANCIAL INTERIM INFORMATION

For the For the
three-month period ended nine-month period ended
July 31, July 31,
------------------------- -------------------------

2008 2007 2008 2007
($) ($) ($) ($)
unaudited unaudited unaudited unaudited
------------------------- -------------------------

Net sales 8,942,007 8,526,260 26,766,768 26,016,559
Cost of sales 1,573,609 1,585,667 4,940,520 4,646,780

Sales incentives 3,697,379 3,538,010 10,971,475 10,808,460
Selling, general and
administrative 3,173,318 2,700,585 9,099,446 8,462,019
Earnings before
income taxes 497,701 701,998 1,755,327 2,099,300
Net earnings 354,168 566,751 1,099,278 1,497,579
Net earnings per
share:
Basic 0.005 0.008 0.016 0.022
Diluted 0.005 0.008 0.016 0.022
Weighted average
number of common
shares outstanding:
Basic 69,994,300 69,994,300 69,994,300 66,593,421
Diluted 69,994,805 69,994,300 70,055,400 69,431,995


As at As at As at
July 31, April 30, October 31,
2008 2008 2007
($) ($) ($)
unaudited unaudited audited
------------ ------------ ------------
ASSETS:
-------
Cash and cash equivalents 6,879,139 5,863,208 3,874,558
Accounts receivable 490,579 601,836 505,366
Other current Assets 4,194,403 3,749,327 3,728,109
------------ ------------ ------------
Total current Assets 11,564,121 10,214,371 8,108,033
------------ ------------ ------------

Other Assets 11,409,233 11,598,814 12,246,573
------------ ------------ ------------
TOTAL ASSETS 22,973,354 21,813,185 20,354,606
---------- ---------- ----------
---------- ---------- ----------
LIABILITIES:
------------
Current Liabilities 4,814,493 4,052,410 3,475,800
Long Term Liabilities 71,945 178,859 393,600
------------ ------------ ------------
TOTAL LIABILITIES 4,886,438 4,231,269 3,869,400
--------- --------- ---------
--------- --------- ---------
SHAREHOLDERS' EQUITY:
---------------------
Share Capital 3,465,548 3,465,548 3,465,548
Other Equity-Stock Options 1,233,111 1,088,016 736,416
Contributed surplus 11,332,143 11,326,406 11,326,406
Retained Earnings 2,056,114 1,701,946 956,836
------------ ------------ ------------

TOTAL SHAREHOLDERS' EQUITY 18,086,916 17,581,916 16,485,206
---------- ---------- ----------
---------- ---------- ----------


NET SALES

For the quarter ended July 31, 2008, net sales were $8,942,007 compared
to $8,526,260 for the same period in 2007, an increase of $415,747 or 4.9%.
Net sales in Canada and net sales to other countries rose by $209,776 or 5%
and $367,716 or 63.9%, respectively. Net sales in the United States, when
converted to Canadian dollars were lower by $161,745 or 4.3%. In US dollars,
network sales in the United States for the quarter ended July 31, 2008 were
$3,472,604 compared to $3,105,888 in 2007, an increase of $367,516 or 11.8%.

For the nine-month period ended July 31, 2008, net sales were $26,766,768
compared to $26,016,559 for the same period in 2007, an increase of $750,209
or 2.9%. This mainly reflects increases in volume in Canada of $685,492 or
5.3% and to other countries of $764,595 or 40.5%. This was offset by a
decrease of $699,878 or 6.2% in the United States after converting US net
sales into Canadian dollars. In US dollars, network sales in the United States
were $10,193,222 compared to $9,340,105 in 2007, an increase of $853,117 or
9.1%.

OPERATING RESULTS

Net earnings were $1,099,278 for the nine-month period ended July 31,
2008 ($354,168 for the quarter), compared to $1,497,579 ($566,751 for the
quarter) for the corresponding periods of 2007. The decrease in net earnings
of $398,301 for the nine-month period, is largely attributable to the hiring
of new executives as well as sales and marketing personnel to support the
strategic plan of the Company, resulting in higher administrative and
marketing remuneration expenses of $735,279 offset by income totalling
$346,562 resulting from foreign exchange gains from the strengthening of the
U.S. dollar and additional interest revenue on our increased cash and cash
equivalents balances during the period.

FINANCIAL SITUATION AND LIQUIDITY

As at July 31, 2008, the Company had a cash position of $6,879,139
compared to $2,185,972 as at July 31, 2007. The Company believes that cash
requirements in the ordinary course of business for next year can be met with
its available cash, cash generated from its operating activities and the
reduction of income tax payments caused by the realization of prior years
income tax losses.

As at July 31, 2008, the Company shows a working capital of $6,749,628
for a ratio of 2.40 compared to a working capital of $4,649,737 with a ratio
of 2.73 as at July 31, 2007. This improvement of $2,099,891 is mainly
attributable to the investment of the majority of the funds generated from the
operations into deposit certificates with short term maturities.

OUTLOOK

Immunotec benefits from a solid balance sheet, skilled and motivated
employees, well-established suppliers, repeat customers and a dedicated
network of distributors. Since last year management implemented and continues
to implement new measures in sales and marketing initiatives and it believes
that these measures will help increase sales during the present year and the
following years.

Management is of the opinion that its investment in current research in
such areas as cancer cachexia, autism, aging and aging-related conditions as
well as clinical trials will enable Immunotec to produce and bring to market
more value-added products thereby continuing to differentiate its products
from competing products.

Product development is on-going, based on recommendations from
Immunotec's Product Development Committee, allowing the company to increase
its product lines within the health and wellness market.

ABOUT IMMUNOTEC

Immunotec operates out of a 37,000 square foot facility located in
Vaudreuil-Dorion, Quebec, Canada as well as a manufacturing facility located
in Blainville, Quebec, Canada and a distribution centre located in Swanton,
Vermont, USA. Immunotec is engaged primarily in the development and marketing
of dietary supplements, food, vitamins, personal care products and natural
health products, some of which are manufactured on its behalf by third
parties. Immunotec's products are distributed and sold in Canada and the
United States through a network marketing system and in other countries under
distributorship agreements.

FORWARD LOOKING STATEMENTS

This press release contains certain forward-looking statements concerning
the future performance of the Company. These forward-looking statements are
based on current expectations. We caution that all forward-looking information
is inherently uncertain and actual results may differ materially from the
assumptions, estimates or expectations reflected or contained in the
forward-looking information, and that actual future performance will be
affected by a number of factors, including technological change, economic
conditions, regulatory change, competitive factors and changes in accounting
rules or standards, many of which are beyond the Company's control. We
disclaim any intention or obligation to update or revise any forward-looking
statements.

The TSX Venture does not accept responsibility for the adequacy or
accuracy of this release.

Contact Information

  • Richard Patte, CA, Executive Vice-President and
    Chief Financial Officer, (450) 510-4445